Free Trial

Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target

Zentalis Pharmaceuticals logo
$2.13 -0.11 (-4.91%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$2.23 +0.10 (+4.69%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zentalis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
3
Buy
7

Based on 11 Wall Street analysts who have issued ratings for Zentalis Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 1 has given a sell rating, 3 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for ZNTL.

Consensus Price Target

$7.50
252.11% Upside
According to the 11 analysts' twelve-month price targets for Zentalis Pharmaceuticals, the average price target is $7.50. The highest price target for ZNTL is $11.00, while the lowest price target for ZNTL is $4.00. The average price target represents a forecasted upside of 252.11% from the current price of $2.13.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ZNTL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zentalis Pharmaceuticals and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZNTL Analyst Ratings Over Time

TypeCurrent Forecast
10/18/25 to 10/18/26
1 Month Ago
9/18/25 to 9/18/26
3 Months Ago
7/20/25 to 7/20/26
1 Year Ago
10/18/24 to 10/18/25
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
6 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
1 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$7.50$6.75$6.14$5.84
Forecasted Upside252.11% Upside117.04% Upside22.61% Upside291.95% Upside
Consensus RatingModerate BuyHoldHoldHold

ZNTL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZNTL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zentalis Pharmaceuticals Stock vs. The Competition

TypeZentalis PharmaceuticalsHealthcare CompaniesBroader Market
Consensus Rating Score
2.64
2.32
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside252.11% Upside1,213.76% Upside18.02% Upside
News Sentiment Rating
Positive News

See Recent ZNTL News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/14/2026 UpgradeHold ➝ Strong-Buy
10/5/2026
Leerink Partners logo
Leerink Partners
2 of 5 stars
Initiated CoverageMarket Perform ➝ Outperform$4.00 ➝ $8.00+217.46%
10/2/2026
Weiss Ratings logo
Weiss Ratings
3 of 5 stars
 Reiterated RatingSell (D-)
9/30/2026 Initiated CoverageEqual Weight$5.00+90.48%
9/16/2026Initiated CoverageOutperform
7/23/2026 Initiated CoverageBuy$11.00+144.44%
7/17/2026Initiated CoverageOutperform$8.00+75.05%
5/22/2026 Reiterated RatingBuy$10.00+141.55%
4/10/2026Boost TargetBuy$6.00 ➝ $10.00+126.24%
11/12/2025Lower TargetEqual Weight$8.00 ➝ $4.00+199.62%
Buy These Five AI Plays Before October 20 (Ad)

Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle is set to begin by October 20. Brown has built a new model portfolio featuring five AI plays tied to this pattern, which he says has repeated with a track record of success in the past. He notes this cycle unfolds outside the traditional stock market, combined with the ongoing AI boom.tc pixel

Click here to see the full details now
11/11/2025 Reiterated RatingNeutral$4.00+195.20%
1/28/2025Lower TargetNeutral$5.00 ➝ $2.20-7.37%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 06:17 AM ET.


ZNTL Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Zentalis Pharmaceuticals is $7.50, with a high forecast of $11.00 and a low forecast of $4.00.

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last year. There is currently 1 sell rating, 3 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ZNTL shares.

According to analysts, Zentalis Pharmaceuticals's stock has a predicted upside of 252.11% based on their 12-month stock forecasts.

Over the previous 90 days, Zentalis Pharmaceuticals's stock had 1 upgrade by analysts.

Zentalis Pharmaceuticals has been rated by research analysts at Jefferies Financial Group, Leerink Partners, Rodman & Renshaw, Weiss Ratings, Wells Fargo & Company, and William Blair in the past 90 days.

Analysts like Zentalis Pharmaceuticals more than other "healthcare" companies. The consensus rating for Zentalis Pharmaceuticals is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ZNTL compares to other companies.


MarketBeat monitors more than a dozen sources for Zentalis Pharmaceuticals analyst ratings, with the most recent rating issued on 10/14/2026.
From Our Partners